We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-0.49%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$312M
AUM Growth
+$302M
Cap. Flow
+$306M
Cap. Flow %
98.25%
Top 10 Hldgs %
48.33%
Holding
84
New
6
Increased
59
Reduced
1
Closed
18

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$30.2M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$25.2M
3
INCY icon
Incyte
INCY
+$20M
4
ALKS icon
Alkermes
ALKS
+$15.4M
5
GILD icon
Gilead Sciences
GILD
+$12.6M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.77M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$121K
3
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
+$107K
4
FOLD
Amicus Therapeutics
FOLD
+$94.6K
5
IMVT icon
Immunovant
IMVT
+$60K

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
2 Miscellaneous 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTCT icon
51
PTC Therapeutics
PTCT
$5.99B
$1.05M 0.34%
21,000
+20,158
+2,394% +$988K
RCKT icon
52
Rocket Pharmaceuticals
RCKT
$397M
$1M 0.32%
63,000
+62,132
+7,158% +$970K
XENE icon
53
Xenon Pharmaceuticals
XENE
$6B
$918K 0.29%
25,500
+24,726
+3,195% +$889K
INSM icon
54
Insmed
INSM
$26.5B
$864K 0.28%
40,100
+39,309
+4,970% +$942K
ARVN icon
55
Arvinas
ARVN
$604M
$756K 0.24%
+17,000
New +$825K
BCRX icon
56
BioCryst Pharmaceuticals
BCRX
$2.52B
$718K 0.23%
57,000
+56,398
+9,368% +$726K
AXSM icon
57
Axsome Therapeutics
AXSM
$10.8B
$625K 0.2%
14,000
+13,465
+2,517% +$673K
IRWD icon
58
Ironwood Pharmaceuticals
IRWD
$701M
$621K 0.2%
60,000
+59,308
+8,571% +$672K
HCM icon
59
HUTCHMED
HCM
$2.16B
$602K 0.19%
68,000
+67,141
+7,816% +$845K
ALLO icon
60
Allogene Therapeutics
ALLO
$722M
$539K 0.17%
50,000
+49,430
+8,672% +$672K
IOVA icon
61
Iovance Biotherapeutics
IOVA
$3.74B
$536K 0.17%
56,000
+52,989
+1,760% +$611K
RLMD icon
62
Relmada Therapeutics
RLMD
$482M
$370K 0.12%
10,000
+9,810
+5,163% +$272K
MDGL icon
63
Madrigal Pharmaceuticals
MDGL
$12.6B
$348K 0.11%
5,350
+4,967
+1,297% +$345K
ALBO
64
DELISTED
Albireo Pharma Inc
ALBO
$312K 0.1%
+16,093
New +$333K
MIRM icon
65
Mirum Pharmaceuticals
MIRM
$6.08B
$193K 0.06%
+9,219
New +$222K
AGIO icon
66
Agios Pharmaceuticals
AGIO
$2.05B
– –
-476
Closed -$21.5K
ANAB icon
67
AnaptysBio
ANAB
$1.7B
– –
-203
Closed -$10K
APLS
68
DELISTED
Apellis Pharmaceuticals
APLS
– –
-1,470
Closed -$32.5K
AVDL
69
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-122
Closed -$50K
BNTX icon
70
BioNTech
BNTX
$28B
– –
-3,847
Closed -$25.8K
BPMC
71
DELISTED
Blueprint Medicines
BPMC
– –
-985
Closed -$19.5K
FOLD
72
DELISTED
Amicus Therapeutics
FOLD
– –
-1,017
Closed -$94.6K
GMAB icon
73
Genmab
GMAB
$21B
– –
-1,857
Closed -$57.2K
IMVT icon
74
Immunovant
IMVT
$9.05B
– –
-233
Closed -$60K
IONS icon
75
Ionis Pharmaceuticals
IONS
$10.4B
– –
-1,703
Closed -$46.1K
1 2
3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2022 Portfolio in Review

As of Q3 2022, International Biotechnology Trust held 84 positions worth $312M, up 3,153% from $9.59M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

International Biotechnology Trust deployed $306M of net new capital in Q3 2022, opening 6 new positions and adding to 59 existing holdings. Its largest new stake was Viatris: 364,000 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $1.77M trimmed.

  • International Biotechnology Trust's largest Q3 2022 buy was Viatris: 364,000 shares worth $3.1M.
  • International Biotechnology Trust added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, an estimated $30.2M increase.
  • International Biotechnology Trust's biggest Q3 2022 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.77M.
  • International Biotechnology Trust fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $121K.
  • International Biotechnology Trust's ten largest holdings make up 48% of its $312M portfolio in Q3 2022.
  • International Biotechnology Trust opened 6 new positions and closed 18 in Q3 2022.
  • International Biotechnology Trust's portfolio value rose 3,153% quarter-over-quarter to $312M.

Based on International Biotechnology Trust's 13F filing for Q3 2022, filed 8 Nov 2022.